anti-EPHB4 CAR T-cell therapy (Kyoto Prefectural University of Medicine)

N/A

Report date: 2025/03/14 16:38:34

Base Information

Drug Nameanti-EPHB4 CAR T-cell therapy (Kyoto Prefectural University of Medicine)

Drug Alias NameEPHB4 CAR T-cells

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionEphrin type-B receptor 4 modulators

TargetsEphrin type-B receptor 4

Therapy Area/IndicationsRhabdomyosarcoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesKyoto Prefectural University

China Registration ClassN/A

Develop Information

Active CompaniesKyoto Prefectural University

Inactive CompaniesN/A

Active IndicationsRhabdomyosarcoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A